Skip to content Inauguração emGrand opening inInauguración en --d --h --m --s · Cadastro VIP ›· VIP sign-up ›· Registro VIP › Abrimos hoje · aguardeWe open today · hold onAbrimos hoy · aguarde Loja aberta! Entrar ›Store open! Enter ›¡Tienda abierta! Entrar ›
Eagle Pharma
Track order WhatsApp

KNOWLEDGE · COMPOUNDS

Cagrilintide

MetabolicClinical trialsPubMed records: 25count from PubMed, not curated
Ask Eagle AI about this compound

Overview

O Cagrilintide é um análogo de longa duração da amilina, hormônio co-secretado com insulina pelas células beta pancreáticas. Atua na saciedade por via diferente do GLP-1, e está sendo desenvolvido pela Novo Nordisk em combinação com semaglutida (CagriSema) para máximo efeito na obesidade. Original in PT-BR

Cagrilintide is catalogued under Metabolic. 1 Eagle article in this library references this compound.

Category
Metabolic
Research stage
Clinical trials — Ensaios Clínicos (Fase III — Novo Nordisk) Original in PT-BR
PubMed records
25 (count from PubMed, not curated)
Eagle articles on this compound
1 Eagle article

Mechanism

Análogo de amilina de longa duração — complementa GLP-1 na saciedade Original in PT-BR

A amilina é um hormônio de 37 aminoácidos co-secretado com insulina pelas células beta. O Cagrilintide é um análogo acilado com meia-vida prolongada (~7 dias vs minutos da amilina nativa). Atua nos receptores de amilina no tronco cerebral (area postrema), promovendo saciedade por uma via neuronal distinta do GLP-1. Enquanto GLP-1 atua predominantemente no hipotálamo, a amilina atua no tronco cerebral — sinais complementares que convergem para reduzir ingestão alimentar. A combinação CagriSema (cagrilintide + semaglutida) explora essa sinergia, mostrando resultados superiores a cada agente isolado. Original in PT-BR

Eagle articles on this compound

Chemical information

CAS
2242827-60-3
Molecular formula
Proprietária (Novo Nordisk) Original in PT-BR
Molecular weight
~3900 g/mol (estimado) Original in PT-BR
Sequence
Análogo modificado da amilina humana Original in PT-BR
Amino acids
Not recorded in the source.
Solubility
Solução aquosa Original in PT-BR
Stability
Dados proprietários Original in PT-BR
Half-life
~7 dias Original in PT-BR
Bioavailability
Alta (SC) Original in PT-BR
Onset
1-2 semanas (saciedade) Original in PT-BR
Routes
SC

Research references

No individual dosing recommendation is given. Values are as recorded in the source, with species and route stated where known.

Third-party research score

65/ 100

Score assigned by the imported source, on its own scale and with no published methodology. Eagle does not compute it, does not verify it and does not endorse it. It appears here to preserve the record, not as an assessment.

  • Perda de peso dose-dependente significativa como monoterapia Original in PT-BR

    PMID: 34986332Year: 2022Species: Not recorded as a structured field in the source.Route: Not recorded as a structured field in the source.Duration: Not recorded as a structured field in the source.Purpose: Not recorded as a structured field in the source.

  • Combinação CagriSema superior a cada componente isolado Original in PT-BR

    PMID: 36652991Year: 2023Species: Not recorded as a structured field in the source.Route: Not recorded as a structured field in the source.Duration: Not recorded as a structured field in the source.Purpose: Not recorded as a structured field in the source.

Safety

Commonly reported

  • Náusea (similar a GLP-1 agonistas)
  • Dor abdominal
  • Constipação

Serious

  • Dados de longo prazo em coleta
  • Pancreatite (risco de classe, não confirmado)

Contraindications

  • Gastroparesia severa
  • Gravidez/amamentação

Warnings

  • Composto em desenvolvimento — não aprovado
  • Uso combinado com GLP-1 apenas sob protocolo clínico

Original in PT-BR — This text was written in Brazilian Portuguese and is shown as recorded. Open the PT-BR page for Cagrilintide.

Lab tests named in the source

  • HbA1c
  • Glicemia de jejum
  • Amilase/lipase
  • Perfil lipídico

The source names the tests and nothing else: no reference values and no thresholds. None were added here. Interpreting a result is a clinical act and is not offered on this page.

Reported protocols

Recorded in the imported source as community protocols. They are NOT Eagle protocols, were not reviewed by Eagle, and are not a dosing recommendation, a prescription or clinical guidance. Values appear exactly as recorded, in the language they were written in.

Dosing summary as recorded

Dose
1.2-4.5mg SC/semana (ensaios) Original in PT-BR
Frequência
1x por semana Original in PT-BR
Status
Em ensaios clínicos — sem protocolo público Original in PT-BR

Vial sizes: 5mg — Peptide Calculator

Interactions

This section brings together two origins. The ones Eagle wrote come from its own curated library, one by one; the rest come from the imported reference material, which records one label and one comment per pair and no source. Neither kind carries a PMID, a population or model, or a degree of certainty. Eagle did not verify the imported ones and does not endorse them. «Compatible», «Caution» and «Avoid» are not an Eagle authorisation or prohibition, and none of this is medical advice.

Reported synergy

Compatible

Caution

  • Retatrutide

    Sobreposição de mecanismo de saciedade Original in PT-BR

  • Tirzepatide

    Overlapping satiety mechanism — the same caution the library already records between cagrilintide and retatrutide. The two appear in the same dosing block, but the library does not describe the combination and gives no joint dose.

Related

← Back to knowledge area